Development of Engineered Cementitious Composites with Conductive Inclusions for Use in Self-sensing Applications

The mechanical and a.c. electrical properties of a new varietal of engineered cementitious composite (ECC) incorporating conductive inclusions are presented. Electrical measurements were undertaken over a wide frequency range while curing and when under uniaxial tensile loading to study the influence of ongoing hydration and multiple microcrack formation on the composite electrical impedance. When presented in Nyquist format, the work shows that conductive inclusions reduce the bulk resistance of the composite while enhancing its polarizability, transforming the classic, single-arc bulk response of typical cement-based materials to a two-arc response. The bulk resistance was shown to increase with time and damage, the former being due to refinement of pore-structure during hydration. Conductive inclusions smaller than the average microcrack width of ECC were shown to improve the sensitivity of the composite to cracking, while those with high aspect ratio resulted in better electrical continuity at low volume fractions

Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer

Asia; Colorectal cancer; PembrolizumabAsia; Cáncer colorrectal; PembrolizumabÀsia; Càncer colorectal; PembrolizumabThe phase 3 KEYNOTE-177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite-instability-high (MSI-H)/mismatch-repair-deficient (dMMR) metastatic colorectal cancer (mCRC). Primary endpoints were progression-free survival (PFS) per RECIST v1.1 by blinded independent central review (BICR) and overall survival (OS). Secondary endpoints were overall response rate (ORR) per RECIST v1.1 by BICR and safety. Here, we report results from the post hoc analysis of patients who were enrolled in Asia from the final analysis (FA) of KEYNOTE-177. A total of 48 patients from Japan, Korea, Singapore, and Taiwan (pembrolizumab, n = 22; chemotherapy, n = 26) were included. At FA, median time from randomization to data cutoff (February 19, 2021) was 45.3 (range 38.1–57.8) months with pembrolizumab and 43.9 (range 36.6–55.1) months with chemotherapy. Median PFS was not reached (NR; 95% confidence interval [CI] 1.9 months–NR) with pembrolizumab versus 10.4 (95% CI 6.3–22.0) months with chemotherapy (hazard ratio [HR] 0.56, 95% CI 0.26–1.20). Median OS was NR (range 13.8 months–NR) versus 30.0 (14.7–NR) months (HR 0.65, 95% CI 0.27–1.55) and ORR was 50% (95% CI 28–72) versus 46% (95% CI 27–67). Grade 3/4 treatment-related adverse events (TRAEs) were reported by two patients (9%) in the pembrolizumab arm and 20 (80%) in the chemotherapy arm. Immune-mediated adverse events or infusion reactions were reported by six patients (27%) and 10 patients (40%), respectively. No deaths due to TRAEs occurred. These data support first-line pembrolizumab as a standard of care for patients from Asia with MSI-H/dMMR mCRC. ClinicalTrials.gov identifier: NCT02563002